With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...
Investor's Business Daily on MSN17h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback